CLDX - Celldex Therapeutics Stock Trading

Celldex Therapeutics (NASDAQ: CLDX) recently announced results from a phase 1b clinical study evaluating CDX-0159 in treating two of the most common forms of chronic inducible hives. In this Motley Fool Live video recorded on July 14, 2021 , Motley Fool contributors Keith Sp...

HAMPTON, N.J., July 16, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the closing of its previously announced underwritten public offering of 6,845,238 shares of its common stock, which includes th...

Shares of Celldex Therapeutics Inc. (NASDAQ:CLDX) traded today at $46.38, eclipsing its 52-week high. So far today approximately 523,000 shares have been exchanged, as compared to an average 30-day volume of 1 million shares. Over the past year, Celldex Therapeutics Inc. has traded in a ...